Education
About Us
Working with TipRanks
Follow Us
Bioatla, Inc. (BCAB)
:BCAB
Earnings Data
Report Date
May 08, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.3Last Year’s EPS
-0.48Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 27, 2025
|% Change Since: -25.64%
|Next Earnings Date:May 08, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant advancements in BioAtla's clinical programs, particularly in the areas of CAB platform development and Phase 2 clinical programs, showing promising therapeutic potential and favorable response rates. Financial strategies are in place to ensure sustainability and future growth, although there are concerns regarding decreased cash reserves and workforce reductions. Overall, the positive clinical progress and strategic positioning outweigh the financial lowlights.Company Guidance
During the BioAtla Fourth Quarter and Fiscal Year 2024 Earnings Call, the company provided comprehensive guidance on various aspects of its business operations and strategic plans. The call detailed the progress of their conditionally active biologic (CAB) platform, highlighting ongoing clinical trials and expected data readouts. Key metrics included the dosing and patient enrollment updates for their EpCAM and CAB CD3 bispecific T-cell engager antibody, with a current focus on achieving target doses of 100 micrograms and 300 micrograms. They reported a 66% and 58% overall survival rate at one and two years, respectively, for patients with MKRAS non-small cell lung cancer in their CAB-AXL-ADC Mec-V program. Financially, BioAtla reported a reduction in R&D expenses to $11.6 million for Q4 2024, down from $22.7 million in the same quarter of 2023, attributed to program prioritization. The company's cash and cash equivalents stood at $49 million at the end of 2024, with efforts underway to extend their runway beyond key clinical readouts anticipated in the first half of 2026. BioAtla is also actively pursuing partnerships for its Phase 2 assets, with discussions underway for CAB R2-ADC Oz-V and initiating talks for their CAB-CTLA-4 antibody, Evalstotug.Progress in CAB Platform Clinical Programs
BioAtla's conditionally active biologic (CAB) platform clinical programs are advancing well, with promising results in several areas. The EpCAM and CAB CD3 bispecific T-cell engager antibody is progressing in dose escalation without reaching the maximally tolerated dose, and multiple patients are experiencing tumor reduction. The CAB-AXL-ADC Mec-V program shows ongoing antitumor activity with confirmed responses among patients with MKRAS mutations, with notable overall survival rates that exceed standard care.
Positive Developments in Phase 2 Clinical Programs
The CAB R2-ADC Oz-V program is demonstrating new responses in treatment-refractory head and neck cancer, with a 100% disease control rate in HPV-positive patients. The CAB-CTLA-4 antibody, Evalstotug, shows a 64% overall response rate and a 100% disease control rate in unresectable/metastatic melanoma, with a favorable safety profile compared to ipilimumab.
Financial Improvements
R&D expenses decreased from $22.7 million in Q4 2023 to $11.6 million in Q4 2024 due to program prioritization, and general and administrative expenses also decreased by $1.3 million. The net loss for Q4 2024 was reduced to $14.9 million from $26.9 million in the previous year.
Corporate Strategy and Future Outlook
BioAtla is extending its runway beyond key clinical readouts in the first half of 2026 by streamlining resources, including a workforce reduction of over 30%. The company is advancing discussions with potential collaborators for its Phase 2 assets, with expectations for significant partnerships.
---
BCAB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
BCAB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 27, 2025 | $0.39 | $0.37 | -5.13% |
| Nov 07, 2024 | $2.22 | $2.10 | -5.41% |
| Aug 08, 2024 | $1.47 | $1.47 | 0.00% |
| May 14, 2024 | $2.61 | $3.00 | +14.94% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Bioatla, Inc. (BCAB) report earnings?
Bioatla, Inc. (BCAB) is schdueled to report earning on May 08, 2025, TBA Not Confirmed.
What is Bioatla, Inc. (BCAB) earnings time?
Bioatla, Inc. (BCAB) earnings time is at May 08, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BCAB EPS forecast?
BCAB EPS forecast for the fiscal quarter 2025 (Q1) is -0.3.
---
